Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test. Antimicrobial resistance (AMR) is one of the biggest global health challenges today. The emergence of multi-drug resistant pathogens has […]
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading →Clinical Development Innovation Press Release
hemotune AG Achieves ISO 13485 Certification, Advancing Breakthrough Nanotechnology in Blood Purification for Improved Patient Care
Schlieren, Switzerland, August 24th 2023 – hemotune AG, a pioneering MedTech startup revolutionizing blood purification [...]
Continue reading →Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading →Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading →Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading →